Podcasts about biocorrx

The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX)(“the Company”), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. CEO and CFO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly. 

BioCorRx® is a healthcare solutions company focused on improving the lives of those struggling with alcohol, opioid, and other addictive disorders. BioCorRx® is a healthcare solutions company focused on improving the lives of those struggling with alcohol, opioid, and other addictive disorders. Even as a pharmaceutical company, they understand that medication alone doesn't solve the addiction. So not only do they curb cravings, they aim to serve clients even when the medication wears off. Edward Bowz, LMFT has an MA in Clinical Psychology from Phillips Graduate Institute and is the Director of Behavioral Health for BioCorRx®.  He was the first mental health practitioner certified by BioCorRx to administer the BioCorRx Counseling Program consisting of their 35 Keys to Sobriety.  He, subsequently, has worked with naltrexone implant patients as a psychotherapist helping them gain a better understanding of how addiction became a part of their lives and address the triggers that most threaten sobriety and tempt relapse. Having studied both Modern and Postmodern therapy, he works to achieve the right blend of Cognitive Behavioral, Solution Focused, Narrative, Psychodynamic, and Family Systems therapies for each client. Edward endeavors to tailor his work to client needs by combining modalities in a way that best suits the client. He joins Erica today to discuss the company, treatment, and their 36 keys for sobriety.**This will be our last episode as Erica and Marsha take a summer hiatus. Stay tuned for encore episodes airing through the summer, and we'll see you in the fall!**

BioCorRx's Executive Vice President, Tom Welch, joins Coruzant Technologies for the Digital Executive podcast. He shares his career journey from operations to leading executive in the tech and pharmaceutical business, developing new ways to beat the addiction crisis here in the U.S.

In this episode we have Ms. Lourdes Felix Chief Executive Officer and Director of BioCorRx and President of BioCorRx Pharmaceuticals Inc. Gurus Lourdes takes us down the path of why being immersed in a market plan pays huge dividends for you and ultimately the patients you help. She underscores the value of market research and how it will not only help in product development but also help you connect and communicate with investors. Gurus Lourdes brings us terrific insights as to what it takes to be a CEO of a vibrant and innovative med tech company!

The Stock Day Podcast welcomed BioCorRx Inc. (OTCQB:BICX)(“the Company”), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Director, CEO, and CFO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly. 

The Stock Day Podcast welcomed BioCorRX (BICX)(“the Company”), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. CFO and COO of the Company, Lourdes Felix, joined Stock Day host Everett Jolly. 

 The Stock Day Podcast welcomed BioCorRx (BICX)(“the Company”), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. COO and CFO, Lourdes Felix, joined Stock Day host Everett Jolly.   

Lourdes Felix, CFO, COO and Director of BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders called in to SmallCapVoice.com, Inc. to talk about the recent launch of the UnCraveRx™ virtual app. UnCraveRx™ is a medically assisted weight loss management program that helps to reduce food cravings combined with on-demand virtual lifestyle support, fitness and nutrition. The UnCraveRx™ App is available now. It is available online www.myuncraverx.com or through the Android or iOS app stores. BioCorRx Inc. (BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance use; please visit www.beataddiction.com for more information on the BioCorRx Recovery Program. The UnCraveRx™ Weight Loss Program is also a medication assisted program; please visit www.uncraverx.com for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit www.BioCorRx.com. This interview may include forward looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $875 from the company on 7-25-19 for 30 days of service.

BioCorRx Inc.'s CEO Mr. Brady Granier joins Health Highlights to discuss being awarded the NIDA grant for $5.7M, a pilot program in Louisiana for alcohol & opioid use disorders, and launch of the UnCraveRx app. # Virtual Fitness App # Lifestyle Support App # Nutrition App # substance abuse addiction # Recovery Program # a non-addictive # medication-assisted treatment (MAT) program # outpatient implant procedure # naltrexone # opioid antagonist # reduce physical cravings for alcohol and opioids # one-on-one counseling program # alcoholism and other substance abuse addictions # BioCorRx Pharmaceuticals # injectable and implantable naltrexone products # development # discovery # future regulatory approval

CEO Brady Granier of BioCorRx, Inc.(OTCQB: BICX) returns to the show to discuss new board member additions, recent private placement, and plans to up list to the NASDAQ. # Alcoholism # Anahiem # implants # independent treatment providers # Naltrexone # out patient programs # pre IND meeting # recovery # support # therapy # opiode use disorder

CEO Brady Granier and CFO Lourdes Felix of BioCorRx, Inc., (OTCQB: BICXD) join host Everett Jolly to talk about details of their NIDA grant application approval, recent reverse stock split, and plans for the development of BICX102. # Alcoholism # Anahiem # implants # independent treatment providers # Naltrexone # out patient programs # pre IND meeting # recovery # support # therapy

President, CEO, and Director of BioCorRx Inc, (OTCQB: BICX) Brady Granier, called in to SmallCapVoice.com to go over the progress the Company has made in 2018. BioCorRx Inc. is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. This interview may include forward looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $750 from the company on 12-11-18 for 30 days of service.

CEO Brady Granier of BioCorRx, Inc., (OTCQB: BICX) rejoins Stock Day to give an update on addiction recovery treatment programs, NIDA funding application, and medication assisted solutions. # OTCQB: BICX # beat addiction # recovery programs # non-addictive # medication-assisted treatment # Alcoholism # Anahiem # implants # independent treatment providers # Naltrexone # out patient programs # pre IND meeting # recovery # support # therapy

Brady Granier joins Bob and Drew to talk about BioCorRx®, a recovery program focused on improving the lives of those struggling with alcohol and opioid addiction. The centerpiece of the program is a proprietary long-lasting implant of Naltrexone, the FDA approved oral based drug, which is proven to substantially reduce cravings for drugs and alcohol. Go to Beataddiction.com or call 888-993-1099 for more details. This implant is not FDA approved but available by prescription.#YOULIVE  This episode is sponsored by ToxProtect from Genotox Labs.

Title: “Medical Help for Addictions” Guest: Brady Granier, RN, BSN; President and CEO of BioCorRx Description: Drug and alcohol addiction are nationwide problems, affecting people of every demographic group. However, new medical therapies are available that can help with addiction treatment. In this week’s episode you’ll learn about how the drug naltrexone, combined with an addiction treatment program developed by BioCorRx, is offering new help for those with alcohol and narcotic addictions. For more information contact: www.beataddiction.com

Brady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, called in to SmallCapVoice.com, Inc. to go over the exciting recent news for the Company. BICX recently announced it up-listing to the OTCQB, their upcoming presentation at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29th, the positive preliminary data from preclinical studies evaluating BICX101, the validating work BICX is doing with the City of Anaheim to treat opioid and alcohol addiction, and more. BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101. For more information on BICX, visit www.BioCorRx.com. This interview may include forward looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

CEO Brady Granier of BioCorRx, Inc., (OTCQB: BICX) returns to the show to talk about out patient procedure to reduce physical cravings, FDA guidance for development plan, and behavioral programs to treat addiction. OTCQB: BICX # beat addiction # recovery programs # non-addictive # medication-assisted treatment #  Alcoholism # Anahiem # implants, independent treatment providers # Naltrexone # out patient programs #  pre IND meeting # recovery # support # therapy

CEO Brady Granier of BioCorRx, Inc., (OTCQB: BICX) rejoins Stock Day to give an update on addiction treatment solutions and upcoming meeting with the FDA. OTCQB: BICX # beat addiction # recovery programs # non-addictive # medication-assisted treatment # Alcoholism # Anahiem # implants # independent treatment providers # Naltrexone # out patient programs # pre IND meeting # recovery support # therapy

Everett Jolly Interviews Brady Grainer, CEO for BioCorRX (BICX), about the Opioid Crisis and BioCorRx's recovery solutions We are pleased to share the following UPTICK Network Stock Day Radio Show and Podcast content. The CEOs interviewed on Stock Day did not incur any charges for their time with Uptick CEO Everett Jolly. Uptick staff is always looking for exciting companies to bring to our interested readers and listeners. Contact us at (602) 441-3474 if you would like further information on the UPTICK Network or Uptick services